Low-Dose Ketamine and Cannabis: What Patients Should Know

Introduction

As cannabis legalization expands across the United States, clinicians providing ketamine therapy increasingly encounter patients who use cannabis -- whether recreationally, for symptom management (pain, insomnia, anxiety), or under state medical cannabis programs. The interaction between cannabis and ketamine has received limited formal study, leaving clinicians to rely on pharmacological reasoning, observational clinical data, and expert opinion.

This article summarizes what is currently known about the cannabis-ketamine interaction and provides practical guidance for patients and prescribers.

Pharmacological Considerations

Overlapping CNS Effects

Cannabis and ketamine both produce central nervous system effects that overlap in clinically relevant ways:

• Dissociation and perceptual disturbance: THC (delta-9-tetrahydrocannabinol), the primary psychoactive component of cannabis, can produce perceptual alterations, derealization, and anxiety at higher doses. Ketamine produces dose-dependent dissociation through NMDA receptor antagonism. The combination may amplify dissociative experiences beyond what either substance produces alone
• Cardiovascular effects: THC increases heart rate (tachycardia), while ketamine produces both tachycardia and blood pressure elevation through sympathomimetic mechanisms. The combined cardiovascular effects may be additive, complicating hemodynamic monitoring
• Cognitive impairment: Both substances impair attention, working memory, and executive function acutely. Combined use extends the duration and severity of cognitive impairment post-treatment
• Anxiolytic and anxiogenic potential: Both cannabis and ketamine have complex dose-dependent relationships with anxiety -- low doses may reduce anxiety, while higher doses or vulnerable individuals may experience increased anxiety or panic

Endocannabinoid System and Glutamate

Emerging neuroscience research has identified interactions between the endocannabinoid system and glutamatergic neurotransmission -- the primary pathway through which ketamine exerts its antidepressant effects. CB1 cannabinoid receptors modulate glutamate release in the prefrontal cortex and hippocampus, regions central to ketamine's antidepressant mechanism. Whether exogenous cannabinoids (THC, CBD) meaningfully modulate ketamine's glutamatergic cascade in humans is unknown, but the theoretical basis for interaction exists.

CBD Considerations

Cannabidiol (CBD) has a different pharmacological profile from THC. CBD does not produce significant dissociation or psychoactive effects, has anxiolytic properties, and has fewer cardiovascular effects. CBD also inhibits several cytochrome P450 enzymes (CYP3A4, CYP2C19) involved in ketamine metabolism, which could theoretically alter ketamine's pharmacokinetics -- slowing clearance and prolonging effects. However, this interaction has not been studied in the context of ketamine therapy.

Clinical Evidence

Limited Controlled Data

No published randomized controlled trials have specifically examined the cannabis-ketamine interaction. The available evidence comes from:

• Observational cohort studies: Some ketamine treatment centers have reported that patients who use cannabis regularly show similar response rates to non-users, though these observations are not rigorously controlled for confounders such as depression severity and comorbidities
• Case reports: Isolated case reports have described amplified dissociative experiences in patients who used cannabis within hours of ketamine treatment, though these reports do not establish causation
• Preclinical studies: Animal models have shown complex interactions between cannabinoid and NMDA receptor systems, with some studies suggesting that cannabinoid agonism may modulate NMDA receptor-mediated plasticity -- but translating preclinical findings to clinical practice is premature

Provider Survey Data

Survey data from ketamine treatment providers suggests a range of clinical approaches. The majority of providers recommend abstaining from cannabis for at least 24 hours before treatment sessions. Some providers do not restrict cannabis use but inquire about it at each session for documentation purposes. A minority of providers consider chronic heavy cannabis use a relative contraindication for ketamine therapy due to concerns about psychological vulnerability and cognitive baseline effects.

Timing Guidance

Given the limited evidence, the following timing recommendations reflect clinical consensus rather than evidence-based guidelines:

Before ketamine treatment:

• Abstain from inhaled cannabis for at least 24 hours before treatment. THC's psychoactive effects from inhalation last 2-4 hours, but residual cognitive and physiological effects persist longer
• Abstain from oral cannabis (edibles, tinctures) for at least 48 hours before treatment, as oral THC has prolonged absorption and effects lasting 6-12 hours with residual effects extending further
• For patients using daily medical cannabis, discuss the feasibility of a treatment-day hold with the prescribing provider

After ketamine treatment:

• Avoid cannabis for at least 12-24 hours after ketamine administration, as ketamine metabolites (norketamine, hydroxynorketamine) remain active during this window
• For IV infusion patients, the longer post-treatment abstinence period (24 hours) is appropriate given higher peak concentrations
• For sublingual/oral ketamine patients using at-home protocols, cannabis should not be used on the same day as ketamine

Impact on Treatment Assessment

One of the most practical concerns with cannabis use during ketamine therapy is its interference with accurate outcome assessment:

• Baseline mood effects: Cannabis acutely alters mood, anxiety, and pain perception. Patients who use cannabis shortly before assessments may produce PHQ-9 or MADRS scores that do not reflect their underlying depressive state
• Side effect attribution: If a patient uses cannabis and ketamine in close temporal proximity, adverse effects (anxiety, dissociation, cognitive impairment, tachycardia) cannot be reliably attributed to either substance
• Treatment response assessment: Clinicians relying on systematic outcome tracking need consistent, unconfounded assessment conditions to make valid dosing and frequency decisions

Provider Perspectives

Clinicians managing this interaction should consider:

• Documentation: Record cannabis use status (frequency, route, timing relative to treatment) at each visit, regardless of whether the practice restricts cannabis use
• Non-judgmental inquiry: Many patients are reluctant to disclose cannabis use if they perceive judgment. Frame inquiries in clinical terms -- "I need to know about all substances you use to manage your care safely and effectively"
• Individualized assessment: A patient using a low-dose CBD product for insomnia presents a different risk profile than a patient smoking high-THC cannabis multiple times daily
• State legal context: In states where cannabis is legal (medical or recreational), providers should address cannabis use as a clinical variable rather than a moral issue, while maintaining clear clinical boundaries around treatment safety

Cannabis Use Disorder Considerations

Patients with cannabis use disorder (CUD) present additional complexity. Heavy, daily cannabis use produces neuroadaptive changes in the endocannabinoid system that may alter the brain's response to ketamine in ways that are not yet understood. Additionally, patients with CUD may have difficulty adhering to abstinence recommendations around treatment sessions. Clinicians should screen for CUD at intake and consider whether the severity of cannabis use warrants treatment modification or additional substance use treatment before or concurrent with ketamine therapy.

Conclusion

The cannabis-ketamine interaction remains poorly characterized by formal research, creating an evidence gap that clinicians must navigate with pharmacological reasoning and clinical caution. The overlapping dissociative, cardiovascular, and cognitive effects of these substances provide a sound rationale for temporal separation. Until controlled studies clarify the interaction, recommending abstinence from cannabis for at least 24 hours before and after ketamine treatment represents a reasonable, safety-oriented approach that most ketamine providers endorse.

References

• Zanos P, et al. Ketamine and Ketamine Metabolite Pharmacology. Pharmacol Rev. 2018;70(3):621-660 — Comprehensive ketamine pharmacology including metabolic pathways
• Katona I, Freund TF. Endocannabinoid Signaling as a Synaptic Circuit Breaker in Neurological Disease. Nat Med. 2008;14(9):923-930 — Endocannabinoid-glutamate system interactions
• National Institute on Drug Abuse: Cannabis (Marijuana) Research Report — NIDA comprehensive overview of cannabis pharmacology and health effects
• Nasrin S, et al. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes. Cannabis Cannabinoid Res. 2021;6(2):150-158 — CBD inhibition of CYP enzymes relevant to ketamine metabolism
• National Academies of Sciences. The Health Effects of Cannabis and Cannabinoids. Washington, DC: National Academies Press; 2017 — Comprehensive evidence review of cannabis health effects
• World Health Organization: Cannabis — WHO overview of cannabis pharmacology and public health considerations